Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Citi
Cantor Fitzgerald
Express Scripts
McKesson
US Department of Justice
Covington
Fuji
Moodys
Fish and Richardson

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,822,637

« Back to Dashboard

Summary for Patent: 8,822,637
Title:Somatostatin analogues
Abstract: The invention provides cyclo[{4-(NH.sub.2--C.sub.2H.sub.4--NH--CO--O-)Pro}-Phg-DTrp-Lys-Tyr(4-Be- nzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.
Inventor(s): Albert; Rainer (Basel, CH), Bauer; Wilfried (Lampenberg, CH), Bodmer; David (Klingnau, CH), Bruns; Christian (Freiburg, DE), Felner; Ivo (Reinach, CH), Hellstern; Heribert (Heitersheim, DE), Lewis; Ian (Riehen, CH), Meisenbach; Mark (Durmenach, FR), Weckbecker; Gisbert (Biel-Benken, CH), Wietfeld; Bernhard (Efringen-Kirschen, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:13/048,932
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,822,637

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING ACROMEGALY ➤ Subscribe
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-002 Dec 15, 2014 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING ACROMEGALY ➤ Subscribe
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-003 Dec 15, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF TREATING ACROMEGALY ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,822,637

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0018891.2Aug 1, 2000

Non-Orange Book US Patents Family Members for Patent 8,822,637

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,473,761 Somatostatin analogues ➤ Subscribe
7,939,625 Somatostatin analogues ➤ Subscribe
9,035,021 Somatostatin analogues ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,822,637

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil PI0112859 ➤ Subscribe
Canada 2416293 ➤ Subscribe
China 1446229 ➤ Subscribe
China 1267451 ➤ Subscribe
Cyprus 1108547 ➤ Subscribe
Czech Republic 20030288 ➤ Subscribe
Czech Republic 302461 ➤ Subscribe
Germany 60133823 ➤ Subscribe
Denmark 1307486 ➤ Subscribe
Japan 2004505095 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
QuintilesIMS
Queensland Health
Cipla
Fish and Richardson
Cerilliant
Express Scripts
Dow
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot